NIH, National Cancer Institute, Division of Cancer Treatment and Diagnosis (DCTD) NIH - National Institutes of Health National Cancer Institute DCTD - Division of Cancer Treatment and Diagnosis

Robustness of gene expression profiling in glioma specimen samplings and derived cell lines

Author(s): Mehrian SR, Reichardt Juergen KV, Ya-Hsuan H, Kremen Thomas J, Liau Linda M, Cloughesy Timothy F, Mischel Paul S, Nelson Stanley F

Publication: Brain Res Mol Brain Res, 2005, Vol. 136, Page 99

PubMed ID: 15893592 PubMed Review Paper? No

Purpose of Paper

This paper performed a comparative analysis of intra- and inter-tumoral gene expression profiles via microarray using specimens that represented two different tumor classes.

Conclusion of Paper

Although present, intra-tumoral variability in gene expression was small compared to the degree of variability observed among tumor classes and patients. The authors conclude that a single tumor sample provides a consistent representation of gene expression for a given tumor specimen. Primary human brain tumor cultures were no longer indicative of parental gene expression profiles after ten passages.

Studies

  1. Study Purpose

    The purpose of this study was to determine levels of intra- and inter-tumoral variability in gene expression via microarray analysis and real-time quantitative RT-PCR (qRT-PCR) in glioblastoma and oligodendroglioma tissue samples. Tumor specimens from 6 patients were analyzed, with 2-4 biopsy samples that were at least 3 cm apart were collected from each tumor.

    Summary of Findings:

    Of the 7129 cDNAs examined via microarray, 931 (or 13%) were differentially expressed. When analyzed by hierarchical clustering, gene expression profiles of samples collected from a single tumor were highly similar, with the exception of a single sample that clustered with two different tumor classes. Histological examination of adjacent regions confirmed that the sample likely contained a mix of cells from the two different tumor classes. The authors conclude that gene expression variance introduced by tumor heterogeneity is small in comparision to that observed between different tumor grades and classes, and between individuals. Results of real-time quantitative RT-PCR (although not shown) confirmed microarray data, as TAF15 expression was reduced in samples from the oligodendroglioma tumor class.

    Biospecimens
    Preservative Types
    • Frozen
    Diagnoses:
    • Neoplastic - Other
    Platform:
    AnalyteTechnology Platform
    RNA DNA microarray
    RNA Real-time qRT-PCR
    Morphology H-and-E microscopy
    Pre-analytical Factors:
    ClassificationPre-analytical FactorValue(s)
    Real-time qRT-PCR Specific Targeted nucleic acid TAF15
    Biospecimen Aliquots and Components Biospecimen heterogeneity Intratumoral sampling (exact positions not specified)
    Preaquisition Diagnosis/ patient condition Glioblastoma brain tumor
    Oligodendroglioma brain tumor
  2. Study Purpose

    The purpose of this study was to determine whether primary human brain tumor culture (after 10 passages) retained parental gene expression profiles using microarray and real-time qRT-PCR (for angiotensinogen and fibronectin 1) analyses.

    Summary of Findings:

    Microarray analysis of primary cell cultures resulted in differential gene expression compared to parental samples, and similar gene expression profiles when compared to one another. Although data was not shown, the authors report angiotensinogen and fibronectin 1 expression were reduced and elevated in primary cell cultures compared to parental samples, respectively, when assessed by real-time qRT-PCR.

    Biospecimens
    Preservative Types
    • None (Fresh)
    Diagnoses:
    • Neoplastic - Other
    Platform:
    AnalyteTechnology Platform
    RNA Real-time qRT-PCR
    RNA DNA microarray
    Pre-analytical Factors:
    ClassificationPre-analytical FactorValue(s)
    Biospecimen Aliquots and Components Number of cell passages 1 passage
    10 passages
    Real-time qRT-PCR Specific Targeted nucleic acid Angiotensinogen
    Fibronectin 1

You Recently Viewed  

News and Announcements

  • April 24, 2024: Biobanking for Precision Medicine Seminar

  • Most Popular SOPs in March 2024

  • New SOPs Available

  • More...